Risk. Competition. Disclosure. Opportunity. From trusted public evidence.
🔍 Check NCT against your scope
Paste any NCT ID. If it falls outside your subscribed therapeutic areas, we'll show you the upgrade path.
Protocol Stratification Engine
> STANDBY. READY FOR PROTOCOL PARAMETERS...
Generate a rescue-lead dossier for a specific NCT ID within your subscribed therapeutic areas. Bulk therapeutic-area discovery is available as an on-demand engagement or via the TALOS add-on (continuous scan + AI-drafted outreach).
Yield Arbitrage | Live Terminal
> STANDBY. CLICK RESCUE LEADS TO BEGIN A SCAN WITHIN YOUR SUBSCRIPTION SCOPE.
📍 ALTERNATIVE RECRUITING SITES
Run 7. RESCUE LEADS in the Arbitrage tab first. For trials at-risk we surface replacement sites; for healthy trials we surface higher-velocity peers in the same geography (real CT.gov data).
📋 SITE & INVESTIGATOR INTELLIGENCE REPORTS
Run 7. RESCUE LEADS in the Arbitrage tab first to load sites. Then select any site or investigator below to generate a premium report.
Answers in minutes, not weeks — at self-serve prices, not consulting rates.
Eichor watches every industry trial across the public registries and tells you what changed the day it changes — whether a site is slipping, a deadline is moving, or a competitor shifts strategy. You get the finding, the plain-language why, and a link to the public source, so you can act on it and defend it.
Eichor is built as a continuous clinical intelligence pipeline—not a consulting firm.
Built on more than a decade of clinical-trial data analysis. The experience behind Eichor comes from years of analyzing public clinical trial and regulatory data. Eichor was created to automate continuous monitoring of those public records, turning daily changes into actionable intelligence for clinical teams.
The platform continuously scans new industry trial registrations and enrollment status changes across public registries. Each week, it publishes Trial Enrollment Watch directly from this live data—assembled, validated, and released by the pipeline itself. Site risk reports are generated on demand in minutes, 24/7, with every claim linked to its original public source.
Human expertise is applied exactly where judgment matters: methodology, quality rules, and customer questions—and nowhere else. Everything else is executed autonomously.
That model is what defines Eichor: intelligence delivered in minutes at self-serve pricing, instead of weeks at consulting rates.
Every verified output—whether a compliance check, alert, or report—is recorded in a tamper-evident, cryptographically signed ledger. Any conclusion can be proven authentic, unchanged, and fully traceable to the evidence it was based on. How our findings are signed →
Eichor is the operating brand of Biomedistats LLC (doing business as Eichor), a U.S. company. All analyses are derived from public-domain data; no patient-level or client-confidential data is used in our public products.
Sites are graded A–F based on their real-world performance, so activation budget goes to locations where patients actually enroll. The platform also identifies named alternative sites when your roster is thin.
Position any Phase II/III protocol against the live competitive field — overlapping trials, shared patient pools and eligibility collisions — from today's registry, before you lock the protocol.
Results-reporting watched across US FDAAA-801, EU CTIS Article 37, the UK's 2025 rules and NIH-grantee reporting — every deadline flagged before it lapses, saving you from the $10k/day penalty.
Track new competitor registrations, biosimilar entries against your reference molecules, and early public deterioration signals that reveal licensing and partnering opportunities months in advance.
24/7 monitoring of registry updates, disclosure deadlines and milestone drift — you get an alert the same day a competing trial, site status or filing changes, each linked to its public source.
Every finding is sealed in a cryptographically signed, hash-chained ledger — so it is evident that what we provided has not been altered. Built-in defense for Legal and Compliance teams.
Live registry intelligence for any trial — each site scored and statused, each signal explained in plain language, and every claim tagged with its public source. Generated on demand, in minutes.
Public registries, FDA databases, and financial disclosures change every day. Eichor's always-on data pipeline continuously converts those changes into operational answers, with every result traceable back to its public source.
Every new industry trial registration and enrollment-status change is monitored daily and autonomously. Enrollment velocity, site friction, investigator–indication fit, and disclosure posture are scored by indication and geography as soon as they change.
Signals only count once they are cross-checked — registry records reconciled against FDA, CMS, and financial filings. Contradictions are either resolved or explicitly flagged, never hidden, and every verified finding is recorded in a cryptographically signed, tamper-evident ledger.
Site-risk reports and investigator dossiers are generated on demand in minutes, ready to plug into your feasibility workflows or CRM. Monitoring alerts reach your inbox the same day a trial, site, or filing changes — not at the next quarterly review.
Priced by how many trials you actively monitor. Browse high-level metadata free; unlock curated Risk Intelligence for the trials you add to your watchlist. Start a free preview →
Any 2 indications in one therapeutic area · 2 monitored trials
≈ $250/mo · billed every 6 months · 5 monitored trials
≈ $500/mo · billed annually · 10 monitored trials
Custom portfolio cap, subgroup structuring, and terms — tailored to your coverage and volume.
Every finding from Eichor is derived from public records and recorded in a cryptographically signed, tamper-evident ledger, so a result you receive today can be demonstrated as unchanged tomorrow. We are explicit about our methods and honest about our limits: no patient data, no opaque models, and every conclusion linked back to its source.
Patent applications have been filed on our composite scoring and multi-source correlation approaches.
Last updated: 2026-05-28 · Effective immediately upon use of the Service
These Terms of Use (the "Terms") form a binding legal agreement between you (the "User" or "Customer") and Biomedistats LLC (operating as Eichor) ("Biomedistats", "we", "us"). By accessing, browsing, registering for, or using any part of the Biomedistats AIOS platform, API, software, content, or any related service (collectively the "Service"), you agree to be bound by these Terms in their entirety. If you do not agree, you must not access or use the Service.
The Service incorporates one or more inventions that are the subject of pending patent applications (collectively, the "Patent-Pending Technology"), including but not limited to the composite distress scoring methodology, the multi-source signal correlation engine, the BMIS-driven investigator resolution graph, the temporal "why-now" window inference, and the anonymised site triangulation procedure. All Patent-Pending Technology, software, algorithms, source code, machine-learning models, data structures, schemas, weights, prompts, user interfaces, designs, trade names, trademarks, and any derivatives thereof (collectively, the "Biomedistats IP") are the exclusive property of Biomedistats and its licensors. Nothing in these Terms transfers to the User any right, title, or interest in the Biomedistats IP other than the limited license expressly granted in Section 3.
Subject to the User's continuous compliance with these Terms and timely payment of all applicable fees, Biomedistats grants the User a non-exclusive, non-transferable, non-sublicensable, revocable, limited license to access and use the Service solely for the User's internal business purposes during the subscription term, and solely within the scope (therapeutic areas, geographies, seats, history depth, and API access) configured on the User's account. The User may not (i) license, sub-license, sell, resell, transfer, assign, distribute, share, time-share, or otherwise commercially exploit the Service to any third party; (ii) modify, adapt, translate, or create derivative works of the Service; (iii) reverse engineer, decompile, disassemble, decrypt, or otherwise attempt to discover the source code, underlying ideas, algorithms, file formats, or non-public APIs of the Service; (iv) use the Service to develop, train, or improve any competing product, service, or model; (v) remove, obscure, or alter any proprietary notices on the Service or its outputs; or (vi) use the Service in any manner that violates applicable law or third-party rights.
The User agrees not to: (a) circumvent or attempt to circumvent any access control, gating, rate limit, seat cap, or other enforcement mechanism; (b) share API keys, credentials, or authentication tokens with any party not authorised on the User's account; (c) automate, scrape, or extract bulk data from the Service except via documented APIs and within the User's licensed limits; (d) introduce malicious code, conduct denial-of-service or penetration testing without prior written authorisation; (e) use the Service outputs to make medical-treatment decisions for identifiable patients (the Service is decision-support for business-development and investment-research purposes only); or (f) use the Service for any unlawful, fraudulent, defamatory, or harassing purpose. Biomedistats may, at its sole discretion, suspend or terminate access for any breach.
All data inputs you provide (NCT IDs, queries, criteria) and any non-aggregated, customer-specific data generated for you remain your property. However, you grant Biomedistats a worldwide, royalty-free licence to (i) process such data as needed to operate the Service, (ii) use aggregated and anonymised metrics for service improvement, model training, benchmarking, and analytics, and (iii) retain audit logs as required for compliance (see Section 11). Outputs derived from the Service (reports, narratives, scores) embed Biomedistats IP and may only be used within your organisation in accordance with Section 3; resale or onward distribution requires a separate written agreement (e.g. white-label licence).
Usage and Interaction Data. For the avoidance of doubt, the licence in clause (ii) above expressly includes Usage and Interaction Data — records of how you interact with the Service, such as which trials (NCT identifiers) you view, the time you spend reviewing site intelligence, and sites you flag or otherwise indicate as a concern. Biomedistats collects this behavioural telemetry and may use it, in pseudonymised and aggregated form, to operate, secure, measure, and improve the Service and to develop, train, and refine its predictive, attention, and risk models. Such data is associated only with a one-way pseudonymous identifier (not your name or email), is reported internally in aggregate only, is never sold, and is not disclosed to other customers in a form that identifies you. You may contact Biomedistats (Section 18) to ask questions about this processing.
The Service aggregates information from public sources including ClinicalTrials.gov, SEC EDGAR, openFDA, NPPES, NIH RePORTER, PubMed, and CMS Open Payments. Biomedistats does not own, control, or guarantee the accuracy, completeness, or timeliness of these third-party sources. The User acknowledges that source data may contain errors, omissions, or outdated information, and that Biomedistats' synthesis and scoring is a probabilistic estimate, not factual certainty. The User assumes all risk associated with reliance on the Service outputs.
The Service is provided for business-decision support only. It does not constitute medical advice, legal advice, financial advice, or an investment recommendation. The User must seek qualified professional counsel before acting on any output of the Service, particularly with respect to clinical-trial decisions, regulatory submissions, securities transactions, or patient care.
Fees for the Service are payable in advance per the User's subscription plan. All payments are non-refundable except as required by applicable law. Subscriptions auto-renew at the end of each billing period unless cancelled at least 24 hours before renewal via the in-app cancellation flow or by written notice to billing@biomedistats.com. Biomedistats reserves the right to modify pricing on 30 days' notice. Failure to pay an invoice within 14 days may result in suspension; non-payment for 30 days may result in account termination and data deletion.
THE SERVICE IS PROVIDED "AS IS" AND "AS AVAILABLE" WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ACCURACY, COMPLETENESS, OR UNINTERRUPTED OPERATION. BIOMEDISTATS DISCLAIMS ALL WARRANTIES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW.
TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL BIOMEDISTATS, ITS OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, OR LICENSORS BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, EXEMPLARY, OR PUNITIVE DAMAGES (INCLUDING WITHOUT LIMITATION LOST PROFITS, LOST REVENUE, LOST DATA, BUSINESS INTERRUPTION, OR COST OF SUBSTITUTE SERVICES) ARISING OUT OF OR RELATING TO THE SERVICE, THESE TERMS, OR ANY DATA OR OUTPUTS, REGARDLESS OF LEGAL THEORY. BIOMEDISTATS' AGGREGATE LIABILITY FOR ANY CLAIM SHALL NOT EXCEED THE AMOUNT PAID BY THE USER TO BIOMEDISTATS IN THE 12 MONTHS PRECEDING THE EVENT GIVING RISE TO THE CLAIM.
The Service maintains a tamper-evident audit log of authenticated requests for security, compliance (including without limitation 21 CFR Part 11 §11.10(e)) and dispute-resolution purposes. The User consents to such logging and acknowledges that log records may be retained for up to seven (7) years.
The User agrees to defend, indemnify, and hold harmless Biomedistats and its affiliates from and against any and all claims, damages, liabilities, costs, and expenses (including reasonable attorneys' fees) arising out of or related to (i) the User's use of the Service, (ii) the User's breach of these Terms, (iii) the User's violation of any law or third-party right, or (iv) any content or data submitted by the User to the Service.
Either party may terminate these Terms for material breach by the other party not cured within 14 days of written notice. Biomedistats may suspend or terminate access immediately for breach of Section 3 (Limited License), Section 4 (Acceptable Use), or non-payment. Upon termination, the User's license terminates and the User must cease all use of the Service. Sections 2, 5, 6, 7, 9, 10, 12, 14, and 15 survive termination.
Each party will protect the other's Confidential Information (including the structure, performance, pricing, and outputs of the Service) using the same degree of care it uses to protect its own confidential information, and at minimum a commercially reasonable standard. The User's account-related data (subscription scope, API key) is Confidential Information of both parties.
These Terms are governed by the laws of England and Wales, without regard to conflict-of-laws principles. The parties submit to the exclusive jurisdiction of the courts of London, England, for any dispute arising under these Terms, except that Biomedistats may seek injunctive relief in any court of competent jurisdiction to protect its intellectual property.
Biomedistats may modify these Terms from time to time. Material changes will be notified by email to the User's account contact and published on this page. Continued use of the Service after the effective date constitutes acceptance.
These Terms constitute the entire agreement between the User and Biomedistats regarding the Service, superseding all prior or contemporaneous agreements. If any provision is held unenforceable, the remaining provisions remain in full force. No waiver of any term is a waiver of any other term, and Biomedistats' failure to enforce any provision is not a waiver of its right to do so later.
For legal notices, IP enquiries, or DMCA-equivalent takedown requests, contact legal@biomedistats.com (click to copy).
Patent Pending Notice: Various features, algorithms, and methodologies of this Service are protected by one or more pending patent applications.
Unauthorised reverse engineering, model extraction, or competitive use is strictly prohibited and may result in legal action under applicable patent law, trade secret law, copyright law, and these Terms.